Spatial mapping of functional pelvic bone marrow using FLT PET

Sarah M McGuire, Yusuf Menda, Laura L Boles Ponto, Brandie Gross, Mindi TenNapel, Brian J Smith, John E Bayouth, Sarah M McGuire, Yusuf Menda, Laura L Boles Ponto, Brandie Gross, Mindi TenNapel, Brian J Smith, John E Bayouth

Abstract

The purpose of this study was to determine the ability of regions identified with bony landmarks on CT imaging to accurately represent active bone marrow when compared to FLT PET imaging. These surrogate regions could then be used to create a bone marrow sparing radiation therapy plan when FLT PET imaging is not available. Whole body (WB) FLT PET images were obtained of 18 subjects prior to chemoradiation therapy. The FLT image of each subject was registered to a CT image acquired for that subject to obtain anatomic information of the pelvis. Seventeen regions were identified based on features of the pelvic bones, sacrum, and femoral heads. The probability of FLT uptake being located in each of 17 different CT-based regions of the bony pelvis was calculated using Tukey's multiple comparison test. Statistical analysis of FLT uptake in the pelvis indicated four distinct groups within the 17 regions that had similar levels of activity. Regions located in the central part of the pelvis, including the superior part of the sacrum, the inner halves of the iliac crests, and the L5 vertebral body, had greater FLT uptake than those in the peripheral regions (p-value < 0.05). We have developed a method to use CT-defined pelvic bone regions to represent FLT PET-identified functional bone marrow. Individual regions that have a statistically significant probability of containing functional bone marrow can be used as avoidance regions to reduce radiation dose to functional bone marrow in radiation therapy planning. However, because likely active bone marrow regions and pelvic targets typically overlap, patient-specific spatial detail may be advantageous in IMRT planning scenarios and may best be provided using FLT PET imaging.

Figures

Figure 1
Figure 1
Axial, sagittal, and coronal views of the registered FLT PET and CT images for one subject. Color wash represents increasing FLT uptake from purple to red and blue approximately equal to SUV 2.
Figure 2
Figure 2
The 17 bone regions (a) identified on one subject's pelvis; the bone regions (b) grouped by similarity in FLT uptake. The subject average SUV mean is largest in the group identified in white. The group identified in grey has the second largest average SUV mean. The group identified in black has the smallest average SUV mean.

References

    1. Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol. 1961;5:255–58.
    1. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1319–39.
    1. Abu‐Rustum NR, Lee S, Correa A, Massad LS. Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer. Gynecol Oncol. 2001;81(1):88–91.
    1. Bolla M, Hannoun‐Levi JM, Ferrero JM, et al. Concurrent and adjuvant docetaxel with three‐dimensional conformal radiation therapy plus androgen deprivation for high‐risk prostate cancer: preliminary results of a multicentre phase II trial. Radiother Oncol. 2010;97(2):312–17.
    1. Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ. Impact of intensity‐modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002;54(5):1388–96.
    1. Dipetrillo T, Pricolo V, Lagares‐Garcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5‐fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):124–29.
    1. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527–39.
    1. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–61.
    1. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin‐based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.
    1. Sanfilippo N, Hardee ME, Wallach J. Review of chemoradiotherapy for high‐risk prostate cancer. Rev Recent Clin Trials. 2011;6(1):64–68.
    1. Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010;116(3):438–41.
    1. Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC. Intensity‐modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57(2):516–21.
    1. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity‐modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.
    1. Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow‐sparing intensity‐modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(5):1504–10.
    1. Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86(1):83–90.
    1. Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity‐modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(5):1356–65.
    1. Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity‐modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(5):1431–37.
    1. Agool A, Schot BW, Jager PL, Vellenga E. 18F‐FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006;47(10):1592–98.
    1. McGuire SM, Menda Y, Ponto LL, Gross B, Juweid M, Bayouth JE. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol. 2011;99(1):49–54.
    1. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase‐1 activity in A549 carcinoma cells. J Nucl Med. 2002;43(9):1210–17.
    1. Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F‐Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44(9):1482–88.
    1. Menda Y, Ponto LL, Dornfeld KJ, et al. Investigation of the pharmacokinetics of 3′‐deoxy‐3′‐[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010;37(4):433–38.
    1. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′‐Deoxy‐3′‐[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem. 2000;243(3):843–46.
    1. Roeske JC, Lujan A, Reba RC, Penney BC, Diane Yamada S, Mundt AJ. Incorporation of SPECT bone marrow imaging into intensity modulated whole‐pelvic radiation therapy treatment planning for gynecologic malignancies. Radiother Oncol. 2005;77(1):11–17.
    1. Liang Y, Bydder M, Yashar CM, et al. Prospective study of functional bone marrow‐sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys. 2013;85(2):406–14.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する